Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis

Gisondi, Paolo; Geat, Davide; Armeni, Patrizio; Bellinato, Francesco; Maurelli, Martina; Girolomoni, Giampiero

doi:10.1080/14712598.2022.2070428

Cited by 8 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7,8 Moreover, following the introduction of biosimilars for adalimumab, therapeutic costs with this drug were lowered. 9 Numerous national guidelines and studies note the good cost effectiveness of starting adalimumab as first-line therapy in psoriasis. 10,11 The different structuring of national healthcare systems leads to the implementation of different treatment pathways that sometimes limits the therapeutic choice.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of anti‐IL‐23 and anti‐IL‐17 after adalimumab failure in psoriatic patients

Mastorino

Susca

Cariti

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

BackgroundMany national guidelines at the European level recommend first‐line therapy based on the anti‐TNF‐alpha adalimumab for treatment of psoriasis and psoriatic arthritis, mainly for economic reasons. Consequently, patients being treated with newer IL‐17 and IL‐23 inhibitors underwent previous unsuccessful first‐line adalimumab‐based therapy.ObjectivesEvaluate the efficacy and safety of IL‐17 and IL‐23 inhibitors after treatment with adalimumab compared to adalimumab‐naive psoriatic patients.MethodsWe retrospectively analysed 1053 psoriatic patients treated with anti‐IL17 and anti‐IL23 agents, which included 68 and 24 adalimumab‐experienced and 399 and 260 bio‐naive patients. Efficacy was assessed with mean PASI, PASI90, PASI100, and <3.ResultsConcerning the achieving of PASI100, PASI90 and PASI < 3 in patients treated with anti‐IL17 agents, no significant differences were observed between adalimumab‐experienced and bio‐naive patients. In patients treated with an anti‐IL‐23 agent, a faster response was observed in bio‐naive patients, with PASI < 3 significantly higher than ADA‐experienced patients at 16 weeks (77% vs. 58% p = 0.048). In a sub‐analysis that evaluated the performance of anti‐IL17 and anti‐IL23 agents in adalimumab‐experienced patients with a history of secondary failure, no significant differences were found. In multivariate analysis of PASI100, only anti‐IL‐17 therapy appeared to have a negative impact at 52 weeks (OR: 0.54 p = 0.04) independently of previous treatment. For PASI90, type of treatment and bio‐naïve status did not seem to have an impact at any time point.ConclusionsAnti‐IL 23 and anti‐IL 17 agents are not significantly different in terms of efficacy in bio‐naive patients or as second‐line therapy after failure with a biosimilar or originator adalimumab.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Moreover, following the introduction of biosimilars for adalimumab, therapeutic costs with this drug were lowered 9 . Numerous national guidelines and studies note the good cost effectiveness of starting adalimumab as first‐line therapy in psoriasis 10,11 .…”

Section: Discussionmentioning

confidence: 99%

Efficacy of anti‐IL‐23 and anti‐IL‐17 after adalimumab failure in psoriatic patients

Mastorino

Susca

Cariti

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Both genetic and environmental factors play a relevant role in psoriasis pathogenesis. Most psoriasis susceptibility loci are related to inflammatory and immunity genes [ 4 , 5 , 6 ]. Environmental and triggering factors include infections (including COVID), stressful life events, medications, skin trauma, and air pollution [ 4 , 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

“…Most psoriasis susceptibility loci are related to inflammatory and immunity genes [ 4 , 5 , 6 ]. Environmental and triggering factors include infections (including COVID), stressful life events, medications, skin trauma, and air pollution [ 4 , 5 , 6 ]. Early events in the development of psoriasis lesions include the recruitment and the activation of plasmacytoid dendritic, which together with natural killer cells and macrophages, secrete cytokines such as IFN-γ, IL-1β, and TNF-α.…”

Section: Introductionmentioning

confidence: 99%

Advanced Glycation End Products and Psoriasis

2023

View full text Add to dashboard Cite

Advanced glycation end products (AGEs) are biologically active compounds formed physiologically throughout a sequence of chemical reactions, to generate highly oxidant-reactive aldehydes that combine covalently to proteins. They accumulate slowly in tissues during ageing but also in metabolic and selected inflammatory disorders. Accumulation of AGEs occurs more rapidly and intensely in the skin and serum of patients with type 2 diabetes, obesity, cardiovascular diseases, chronic renal insufficiency, and non-alcoholic fatty liver disease and also in the skin of patients with psoriasis. All of the above conditions are intimately associated with psoriasis. Interaction of AGEs with their receptors (RAGEs) stimulates cellular signaling with the formation of reactive oxygen species and activation of nuclear factor kappa light chain enhancer of activated B (NF-kB), which is a key regulator in the expression of inflammatory mediators and the production of oxidative stress. Thus, AGEs may play an interesting pathogenic role in the intersection of inflammatory and metabolic diseases, may represent a biomarker of inflammation and a potential target for novel therapeutic strategies. This is a narrative review with the objective to summarize current evidence on the role of AGEs in psoriasis.

show abstract

“…At the same time, slight differences in their formulation and production lead the drugs to have distinct rates of adverse effects and overall patient compliance 12 . Their widespread use in clinical practice is also linked to economic advantages because of their lower price compared to the original molecules, 13 leading to a reallocation of budgets 14 that would improve patient care and grant and an easier access and adherence to treatment 15 . On the other hand, the class of anti‐IL mAbs includes two IL‐17A ligands, one IL‐17 receptor A mAb, one anti IL‐12/23 mAb and three anti IL‐23 mAbs compounds whose efficacy and safety are being widely explored in literature 16–18 …”

Section: Introductionmentioning

confidence: 99%

Bio‐experienced psoriasis patients treated with anti‐interleukin monoclonal antibodies are less likely to achieve PASI 90, PASI 100, PASI ≤ 1 and ≤3: Results from a cohort of 305 patients

Margiotta

Michelucci

Panduri

et al. 2023

JEADV Clinical Practice

View full text Add to dashboard Cite

BackgroundMonoclonal antibodies (mAbs) directed against Tumor Necrosis Factor alpha (TNF‐α) and interleukin (IL)‐17 and 23 represent the ultimate therapeutic strategy in treating psoriasis patients, but scientific literature still does not provide conclusive results regarding the possible influence of previous biological therapies on real‐life therapeutic response.ObjectivesThe objective of our work was to investigate any putative difference in the achievement and maintenance of PASI 75, 90 and 100, as well as the probability to achieve absolute PASI≤1 and ≤ 3, between 305 bio‐naïve and bio‐experienced patients treated with anti‐IL mAbs.MethodsA comparison between previous biologic and clinical factors, including relative and absolute PASI, was carried out through chi square test. Survival curves for the achievement of PASI 75, 90 and 100 and their differences were evaluated, performing a multivariate analysis (Confidence Interval 95%; p‐value <0.0.5).ResultsPrevious biologic therapy resulted associated with a lower rate of PASI 75 (HR 1,339; p‐value 0,034), 90 (HR 1,365; p‐value 0,0031;) and 100 achievement (HR 1,596; p‐value 0,007).The survival curves showed how bio‐experienced patients were less likely to reach and maintain PASI 90 (naïve vs anti‐IL: p = 0.001; naïve vs anti‐TNF + anti‐IL: p <0.001) and PASI 100 (naïve vs anti‐TNF‐α: p = 0.014; naïve vs anti‐IL: p <0.001; naïve vs anti‐TNF‐α + anti‐IL: p < 0.001)]. Moreover, bio‐naïve patients showed a greater probability to achieve both absolute PASI≤3 and ≤ 1 (p<0.001)ConclusionsOur results represent a real‐life analysis on the impact of previous biologic therapy in the clinical efficacy of anti‐IL. Even if further studies with bigger samples are needed to extrapolate absolute considerations, we provided the first evidence on the burden of the bio‐naïve condition for a greater achievement of both PASI 90, 100 and the probability to achieve PASI≤1 and ≤ 3.This article is protected by copyright. All rights reserved.

show abstract

Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis

Cited by 8 publications

References 32 publications

Efficacy of anti‐IL‐23 and anti‐IL‐17 after adalimumab failure in psoriatic patients

Efficacy of anti‐IL‐23 and anti‐IL‐17 after adalimumab failure in psoriatic patients

Advanced Glycation End Products and Psoriasis

Bio‐experienced psoriasis patients treated with anti‐interleukin monoclonal antibodies are less likely to achieve PASI 90, PASI 100, PASI ≤ 1 and ≤3: Results from a cohort of 305 patients

Contact Info

Product

Resources

About